B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1
Oncology
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1?
There are 1 clinical trial targeting B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 tracked by BioSniper.
What is the prevalence of B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1?
The estimated prevalence of B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 is approximately 56.0 per 100,000 population.
Deep-dive into B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis